Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Pediatr Clin North Am. Author manuscript; available in PMC 2013 April 1.
Published in final edited form as:
PMCID: PMC3368378

Making Sense of the Cytokine Storm: a conceptual framework for understanding, diagnosing and treating hemophagocytic syndromes


Cytokine Storm Syndromes (CSS) are a group of disorders representing a variety of inflammatory etiologies with the final common result of overwhelming systemic inflammation, hemodynamic instability, multiple organ dysfunction, and potentially death. The hemophagocytic syndromes hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) represent two clinically similar CSS with an unknown degree of pathoetiologic overlap. The clinical presentations of all CSS can be strikingly similar, creating diagnostic uncertainty. However, clinicians should avoid the temptation to treat all CSS equally, as their inciting inflammatory insults vary widely. Failure to identify and address this underlying trigger will result in delayed, inoptimal, or potentially harmful consequences. This review endeavors to place the hemophagocytic syndromes HLH and MAS within a conceptual model of CSS, and thus provide a logical framework for diagnosis and treatment of CSS of suspected rheumatic origin.

Keywords: Cytokine storm, Macrophage Activation Syndrome, Hemophagocytic Lymphohistiocytosis, Sepsis



In the days before germ theory, the term “sepsis” (from the Greek sepo, “I rot”) was applied to all states of uncontrolled inflammation. Today we reserve the moniker “sepsis” to refer to overwhelming inflammation in the context of a systemic infection (although even this definition can be ambiguous). The term “Cytokine Storm Syndrome” (CSS) was developed to accommodate the observation that multiple inflammatory causes can result in a disease that appears very similar to sepsis. The unifying feature of CSS is a clinical and laboratory phenotype suggestive of massive inflammation progressing to multiple organ dysfunction syndrome (MODS) and eventually death, a final common pathway.

Examination and Laboratory Findings

The clinical constituents of this pathway can include fever, tachycardia, tachypnea, hypotension, malaise, generalized swelling, altered mental status, diffuse lymphoadenopathy, organomegaly (particularly of the liver and spleen), and often erythematous or purpuric rash. In response to the desire by intensive care practitioners to standardize hemodynamic management of CSS, criteria for Systemic Inflammatory Response Syndrome (SIRS) were proposed in 19921 and have been amended a number of times, notably to accommodate pediatric practice2 (Table 1).

Table 1
Pediatric SIRS Criteria

CSS also have a number of common laboratory abnormalities. Hematologic parameters like leukocytosis or thrombocytosis can indicate the acute phase response. Alternatively, elevated cell counts can drop precipitously as a feature of nearly all CSS, suggesting consumption. Clinicians can also take advantage of a host of non-specific acute phase reactants, including erythrocyte sedimentation rate (ESR), c-reactive protein, procalcitonin, serum amyloid a, ferritin, and fibrinogen among others. Notably, and akin to acute cytopenias, an acute drop in ESR and fibrinogen are most associated with Macrophage Activation Syndrome (MAS), but can be seen in any cytokine storm syndrome and often suggest active disseminated intravascular coagulopathy (DIC). Screens for coagulopathy such as fibrin split products and d-dimer are often elevated in CSS even in the absence of overt DIC, suggesting subclinical endothelial activation. Likewise, hypoalbuminemia is frequently observed and likely represents systemic capillary leak. Routine testing often reflects various organs in distress including the liver, pancreas, and kidneys. Such tests are rarely capable of distinguishing direct inflammatory damage from that induced by insufficient oxygen delivery.

The Elusive Hemophagocyte

Hemophagocytes are activated macrophages seen histologically to be have engulfed other hematopoietic elements (erythrocytes, leukocytes, or platelets, see Figure 1). Hemophagocytes are the pathologic hallmark of Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS). However, hemophagocytes are not essential to the diagnosis of HLH3, and can be seen in juvenile arthritis patients without overt MAS4. Additionally, hemophagocytes are found commonly in a host of other inflammatory states including sepsis5 and following bone marrow transplant6. Whether hemophagocytes are inflammatory, anti-inflammatory, or serve different roles in differing diseases is a matter of ongoing study.

Figure 1
Hemophagocyte seen in the spleen of a WT mice treated with TLR9 stimulation and IL-10 blockade. *=engulfed RBC (so-called ghost cell); #=engulfed leukocyte.


An analysis of the underlying pathoetiology of all CSS supports this simple but essential postulate: cytokine storm results from excessive proinflammatory stimuli, inadequate regulation of inflammation, or elements of both. Proinflammatory stimuli can include antigens, superantigens (compounds that trigger non-specific but massive activation of T-cell receptors), adjuvants (such as toll-like receptor (TLR) ligands, for an excellent review of TLRs in infection and autoimmunity see7), allergens (antigens triggering an allergic response), and proinflammatory cytokines themselves. Anti-inflammatory mechanisms can be humoral or cellular and seek to dampen or terminate a proinflammatory pathway. Table 2 provides several examples of both pro-inflammatory stimuli and anti-inflammatory mechanisms. Defects leading to excessive pro- or inadequate anti-inflammatory responses can be host-derived or environmental.

Table 2
Common examples of pro- and anti-inflammatory contributors to CSS

Host Factors

Conventional Immunodeficiencies

Sepsis being quite common among otherwise immunologically normal hosts, it is easy to forget that there are likely hundreds of genetic and epigenetic risk factors for the development of sepsis. Patients with immunodeficiencies should be considered at risk for CSS by virtue of their inability to effectively clear the proinflammatory elements of an infection. Persistent infection provides a rich source of both antigen and adjuvant that, as the infection worsens, can quickly overwhelm the body’s ability to regulate inflammation.

The primary immunodeficiencies encompass defects in both innate and adaptive immunity, and include entities such as severe combined immunodeficiency (SCID), X-linked agammaglobulinemia, Common Variable Immunodeficiency, Chronic Granulomatous Disease, and complement component deficiencies, among many others (see for a thorough, searchable review of immunodeficiency syndromes8). Other host-derived immunodeficiency states such as extremes of age and malnutrition can contribute to the inability to effectively clear inflammatory stimuli.

Familial Hemophagocytic Lymphohistiocytosis (fHLH)

Familial HLH is a cytokine storm syndrome usually occurring in younger children who present with immense inflammation, pancytopenias, and other features of the final common pathway. Such patients’ disease is usually triggered by viral infection, and patients are unable to effectively clear the virus. Familial HLH, by definition, occurs in individuals with little to no ability of their Natural Killer (NK) cells and cytotoxic T-cells to kill targeted cells3. The genetic defects associated with fHLH all relate to the packaging, exocytosis, or function of cytotoxic granules (see Table 3)9, with perforin gene defects being the most common and best studied. Similar to SCID patients, children with fHLH will eventually succumb to their illness without eventual allogeneic bone marrow transplantation3. Animal models of HLH suggest that uncontrolled activation of cytotoxic T-cells by antigen presenting cells (APCs) drives the disease, with interferon-γ (IFNγ) being the primary pathogenic cytokine1012. Other inflammatory pathways are also involved in these models, as recently illustrated by the crucial role of MyD88 in disease development13. MyD88 is a critical signaling molecule downstream of IL-1 receptor and TLR signaling, and as discussed below, may provide some common inflammatory link to MAS.

Table 3
Genetic disorders associated with the occurrence of HLH*

The absence of functional cytotoxicity makes it impossible for T-cells to terminate the stimulatory responses they receive from APCs. In this way, HLH may rightly be viewed as a primary immunodeficiency: these patients’ genetic defect makes it impossible for them to clear infection and terminate T-cell stimulation by APCs. Similar to sepsis, in fHLH it is the uncontrolled immune response to infection that causes the cytokine storm.

Interestingly, the limited studies to date in patients with HLH have not yet borne out a major role for IFNγ. Microarray of RNA from HLH patients’ peripheral blood mononuclear cells (PBMCs) did not show induction or suppression of IFNγ-inducible genes14. Rather, signaling downstream of various inflammatory cytokines such as IL-6, IL-1, and IL-8 was upregulated. Accordingly, IL-10 (a potent anti-inflammatory cytokine) signaling was highly upregulated. Genes governing NK cell activities, T-cell differentiation, and TLR signaling were also downregulated14. Such genes downregulated in sick patients supports a possible pathogenic role for these pathways. Of note, only a minority of patients in this study had identified mutations14, suggesting that our knowledge of all of the genetic defects that lead to fHLH is incomplete.

X-linked lymphoproliferative Syndromes (XLP) and Epstein Barr Virus-related HLH (EBV-HLH)

While in fHLH, it appears that a genetic inability to kill infected, activating APCs results in uncontrolled stimulation of T-cells. Other genetic defects have been associated with HLH as well. The X-linked Lymphoproliferative Syndromes XLP1 & XLP2 are both marked by a tremendous susceptibility to EBV infection, often resulting in an HLH phenotype15. XLP1 is caused by a mutation in SAP, an intracellular protein important for regulating IFNγ signaling. XLP2 is due to mutations in XIAP, a protein known to inhibit apoptosis. How XIAP mutations contribute to HLH is unknown. Nonetheless, HLH in XLP patients nearly always occurs in the context of EBV infection15.

Even in the absence of a known mutation, chronic EBV infection is a risk factor for the development of HLH. In EBV-HLH, viral loads correlate with the progression or improvement of disease16, suggesting persistent pro-inflammatory stimulation is important for disease maintenance. The association of EBV with various other lymphoproliferative diseases and hematologic malignancies suggests this virus has a propensity for uncontrolled immune activation and proliferation16.

Macrophage Activation Syndrome

The nomenclature among CSS does not lend itself to clear delineations. For the purposes of this review, we will define Macrophage Activation Syndrome (MAS) as a cytokine storm syndrome occurring in the context of a rheumatic disease and not otherwise associated with severe infection. Others have referred to hemophagocytic syndromes not associated with fHLH mutations as secondary or reactive HLH3,17. MAS occurs in between 10 and 50% of patients with systemic juvenile idiopathic arthritis (sJIA) depending on its definition4. MAS also complicates systemic lupus erythematosus (SLE), Kawasaki Disease, and more rarely a host of other rheumatic conditions18,19. That MAS appears to occur more commonly in some rheumatic illnesses than others suggests that MAS-prone diseases may share a similar mechanistic propensity for cytokine storm. Additionally, the fact that MAS occurs only very rarely amongst patients with inflammasome disorders (illnesses associated with genetic defects known to cause excessive cytokine activation20) suggests that proinflammatory conditions alone are not sufficient to result in MAS.

Efforts to understand the pathogenesis of MAS have focused on sJIA patients, as this appears to be the most susceptible population. A number of studies have suggested that, like in fHLH, a defect in cytotoxic function plays a role in the development of MAS21,22. More recent studies have even found an increased risk of developing MAS in sJIA patients harboring polymorphisms associated with fHLH genes23,24. However, since many sJIA patients with NK dysfunction do not develop MAS, it is possible that cytotoxic cell dysfunction may be a non-specific finding in sJIA that correlates with MAS.

Like in fHLH, IL-1/TLR signaling may be important for the development of MAS. Studies looking at PBMC RNA microarrays from newly-diagnosed, untreated sJIA patients identified regulation of the IL-1 and TLR pathways in those patients at higher risk for MAS25. Additionally, polymorphisms in a gene critical for TLR signaling (Interferon regulatory factor 5) are associated with a four-fold higher risk of MAS among sJIA patients26.

The only animal model of MAS to date utilizes repeated TLR9 stimulation in otherwise genetically normal mice27. TLR9 is a bacterial and viral DNA sensor implicated in bacterial and EBV infection and SLE28,29. As in HLH models, the TLR9 model supports an important role for IFNγ in the development of disease27. Perhaps most interestingly, IL-10 is critical in this model for protection from severe disease and hemophagocytosis. Further supporting a protective role for IL-10 in MAS, two genomic studies have associated low IL-10 expressing polymorphisms with sJIA30,31. In contrast, IL-10 inhibition in a fHLH model did not appear to hasten disease10, suggesting that this regulatory mechanism may be more important in some CSS than others.

Measurements of serum cytokines from MAS patients have done little to clarify a single pathogenic pathway. IL-18, macrophage colony stimulating factor (M-CSF), neopterin, and IL-6 have all been shown to be elevated in MAS patients, but variably depending on the underlying disease32,33. This suggests that different rheumatic conditions exploit different pathways to arrive at an MAS phenotype.

Malignancy-Associated Hemophagocytic Syndromes (MAHS)

Hemophagocytic syndromes occur in the context of malignancy under two circumstances: first, MAHS can occur as a masking feature of the presentation of various hematolymphoid malignancies, and second, they may complicate the initial course34. The types of malignancies in each group are different. T-cell leukemias and lymphomas are often masked by a hyperinflammatory MAHS state, while B-cell leukemias and germ cell tumors are often complicated by MAHS34. When MAHS masks a malignancy, it is often the case that neoplastic cells are producing macrophage-activating cytokines such as IFNγ and CD25, whereas HLH complicating a malignancy usually occurs when severe infection complicates an intrinsically or iatrogenically immunocompromised state34.

Environmental Factors

We have described that infection plays a key role in the induction of genetic causes of CSS like fHLH and XLP. However, even in normal hosts environmental agents frequently provide sufficient proinflammatory stimuli (or inhibition of regulatory processes) to drive a CSS. More plainly, anyone can get septic.


As stated, infection provides (at least) two important proinflammatory stimuli: antigen and adjuvant. Antigenic stimulation is necessary for a specific response as well as generation of memory, while adjuvant provides the first stimulus to cells of the innate immune system. While theoretically any infection can provide sufficient stimulation to generate cytokine storm, this section will focus on infections commonly associated with hemophagocytic syndromes.


It was previously held that bacterial infections were uncommon causes of hemophagocytic syndromes. A review spanning 1979 to 1996 identified only 11 cases of bacterial-induced HLH, but 149 cases of viral-induced HLH 34. However, this understanding preceded widespread testing for mutations associated with XLP and fHLH, and thus many viral-associated HLH cases would now be classified as primarily genetic. Additionally, there is an increasing appreciation for the consumption, cytopenias, and hemophagocytosis in severe infection5,17.

Bacterial infection provides a rich source of antigenic as well as TLR stimulation. However, if host defects in cellular cytotoxicity are critical to the development of hemophagocytic syndromes, it may be that most bacteria do not require this mechanism for their efficient clearance. Interestingly, a model of secondary HLH utilizes the intracellular bacteria salmonella enterica to drive disease35, suggesting that perhaps viruses and intracellular bacteria exploit a common immunologic weakness in driving hemophagocytic syndromes.


It is not entirely clear why viral infections should be especially predisposed to hemophagocytic CSS. IFNγ is made in abundance by a variety of hematopoietic cells in response to viral infection, and may be particularly important in facilitating hemophagocytosis36. EBV, cytomegalovirus, and other γ-herpesviruses are the infections most commonly associated with HLH34, and this may have to do with their predilection for triggering TLR9, which has been associated in animal models with MAS27,28. Additionally, certain viruses alter the immune response to infection and may predispose to cytokine storm. The EBV genome encodes an IL-10 homologue that may alter the host immune response to infection37. Additionally, there are numerous case reports of HLH complicating both the presentation of and opportunistic infections in human immunodeficiency virus infections38.

Other Infectious Agents

Fungal and parasitic infections are also capable of inducing a robust immune response. Again, it may be instructive there are only rare case reports of hemophagocytic disease complicating highly cytokine-driven infections such as plasmodium falciparum39. Alternatively, it may be that fungal and malarial sepsis are common enough causes of cytokine storm that a thorough evaluation for defective cytotoxicity or hemophagocytosis is rarely undertaken.

Immunosuppressive therapy

As suggested in relation to MAHS, chemotherapy not only inhibits the ability to clear infections, but may alter the regulatory machinery necessary for modulating the immune response to infection.


Allergens are a potent source of antigenic stimulation without infection. Prolonged exposure to high doses of the allergy-associated cytokine IL-4 resulted in hemophagocytosis in mice40. However, this model of hemophagocytic disease occurrs independent of IFNγ. Data regarding hemophagocytosis in human anaphylaxis or other severe allergic reactions, such as DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) are lacking.


We and others have supported the notion that the universe of CSS share a similar final phenotype17. Additionally, we have shown that a variety of host-derived and environmental insults can result in this phenotype. We will later show that optimal treatment varies widely between CSS. Thus, distinguishing among these syndromes is critically important if one wishes to interrupt the final common pathway and restore inflammatory homeostasis.

The workup of any CSS must begin with an assessment of hemodynamic stability and appropriate intensive care intervention. Next, an assessment of organ dysfunction and coagulopathy is critical, but rarely provides specific diagnostic information. Finally, a thorough evaluation for infection or malignancy should preempt a diagnosis of HLH or MAS.

Cytopenias and Macrophage Activation

Diagnostically, the pattern or trend of hematologic and immunologic values can be useful. While sometimes observed in severe sepsis, acute drops in all three cell lines are characteristic of the hemophagocytic syndromes. Pancytopenia occurring prior to the onset of systemic inflammation should raise concern for malignancy. Elevated triglycerides may be a serum marker for HLH and MAS.

As its name implies, MAS is accompanied by markers of macrophage activation. Most notably, ferritin levels in MAS and HLH are often above 10,000 ng/mL, while such values are in the range of a few hundred ng/mL in sepsis3,41. Other markers of macrophage activation, such as neopterin, soluble CD163, and soluble CD25 (aka soluble IL-2 receptor α, or sIL2Rα), may show more clinical utility as they become available outside of reference laboratories42,43.

Tests of Cytotoxic Dysfunction

As mentioned previously, fHLH is characterized by the paralysis of cellular cytotoxicity, and this mechanism may be important in MAS as well. Such cytotoxicity is mediated through the exocytosis of preformed lytic granules within cytotoxic cells9. Increasing arrays of tests are available to assess this exocytic and cytotoxic function. Many centers are able to perform a standardized assay of NK cell cytotoxic function, which assesses the ability of NK cells to lyse a tumor cell line that lacks major histocompatibility complex (MHC) type I. This ex vivo assay is useful in screening for CSS associated with cytotoxic dysfunction, but impaired NK function in this assay is frequently described in sepsis and MODS as well17.

Other assays of cytotoxic dysfunction are increasingly available in reference laboratories. One can test for the presence of the perforin protein in cytotoxic cells through flow cytometric assays. Additionally, screening for a defect in fusion of cytotoxic vesicles to the cell membrane can be accomplished by evaluating for “mobilization” of CD107a (aka lysosomal associated membrane protein 1, or LAMP1)44. Once a defect of cellular cytotoxicity is strongly suspected, genetic testing for fHLH-associated mutations should proceed (Table 3).

Diagnostic Criteria

In 2004 the Histiocyte Society revised criteria for the diagnosis of both familial and reactive HLH (HLH-04, Table 4)3. While the performance of these criteria against other CSS has not been formally evaluated, increasing data would suggest that they do not offer a high degree of specificity for fHLH17.

Table 4
Diagnostic Guidelines for HLH

In recognition that distinction of MAS from a flare of its underlying disease presented a diagnostic challenge, Ravelli et al have created criteria for the distinction of MAS from a flare of sJIA (Table 5)41,45. These criteria were based on retrospective evidence of features that may distinguish sJIA from MAS and have yet to be prospectively validated.

Table 5
Preliminary diagnostic criteria for MAS complicating SJIA (11)


As with diagnosis, treatment of CSS must begin by addressing the final common pathway: intensive care of hemodynamic instability, support of specific organ dysfunction, and correction of coagulopathy. However, such supportive measures are unlikely to be sufficient to re-establish homeostasis without also addressing the factors driving cytokine production and effect.

Altering the Environment

For CSS of primarily environmental etiology, elimination of the offending microbe, allergen, or cytotoxic agent when possible may be all that is needed to allow restoration of homeostasis. An assessment for underlying immunodeficiency should help guide empiric treatment of suspected sepsis. MAHS, while of intrinsic origin, require a similar strategy: clear the source of inflammatory stimulation, in this case neoplastic cells.

While supportive care and antimicrobials may be sufficient to treat sepsis, antimicrobial use is indicated in any CSS where a contributing treatable pathogen is suspected. For example, a patient with a known defect in cytotoxicity infected with a herpesvirus would likely benefit from appropriate antiviral therapy.

In addition to clearing pro-inflammatory stimuli, treatments that alter immune response to such stimuli are emerging as potentially beneficial. Agents such as hydroxychloroquine, that are purported to act through inhibition of TLR signaling, are useful in treating SLE. More specific inhibitors of TLR signaling are now being considered for use in autoinflammatory disorders46.

Managing the Host Defect

Conventional Immunodeficiency

While elimination of the opportunistic pathogen is critical, supplementation of immune responses may be beneficial. In conventional immunodeficiency, this is best achieved preventatively with IV Immune globulin, GM-CSF, and/or appropriate vaccination. Acute supplementation of the immune response may also be beneficial, and it is unclear to what extent IVIg treatment successes in hemophagocytic syndromes are attributable to clearance of infection versus direct anti-inflammatory effects17,39.

Hemophagocytic Lymphohistiocytosis

HLH-04 provided treatment recommendations for both fHLH and reactive HLH that utilize corticosteroids, cyclosporine, and etoposide as a bridge to transplant3. The goals of acute treatment of fHLH are to manage the immune response and preserve organ function in anticipation of allogeneic bone marrow transplantation. While some alterations in this protocol have been proposed47, HLH-04 remains the foundation of fHLH treatment.

However, it is increasingly recognized that most disorders meeting HLH-04 criteria will not require such aggressive immunosuppression17. Additionally, chemotherapeutic strategies similar to HLH-04 carry a high risk for iatrogenic infection and hematologic malignancy17,48. This concern for excessive toxicity has led to the use of more specific cytotoxic treatments in diseases with more discreet target populations. For example, rituximab has been shown to be effective in EBV-HLH, potentially due to cytotoxic effects on infected cells49, and IVIg may be effective in secondary HLH and MAS17,50.

Macrophage Activation Syndrome

The management of MAS is far from standardized and remains controversial. Most agree that high doses of corticosteroids are useful, but the mechanisms by which corticosteroids exert this beneficial effect are unclear. One postulated mechanism is that they help skew macrophages away from an M1, or proinflammatory differentiation state, toward a more regulatory or scavenger state51. In this case, one may expect corticosteroids to be effective in the treatment of any CSS exhibiting significant macrophage activation.

While many practitioners treat MAS with an HLH-04-like approach, less toxic strategies targeted at specific inflammatory defects have emerged. Accumulating evidence suggests that anakinra, a recombinant IL-1 receptor antagonist, may be beneficial in MAS. The successful treatment of sJIA with anakinra52,53, coupled with evidence that IL-1 receptor signaling may be implicated in MAS25, support IL-1 inhibition as a viable strategy. Indeed, several practitioners have reported successful treatment of MAS with only corticosteroids and anakinra54,55. It is unclear if IL-1 inhibition is a viable strategy for MAS in general, or whether it is uniquely suited to a potentially IL-1 mediated disease such as sJIA.


The hemophagocytic syndromes MAS and HLH overlap considerably with other CSS, and share a final common pathway with them. Laboratory findings such as dropping cell counts, dropping ESR, elevated ferritin, NK dysfunction, and hemophagocytosis that were once felt to be unique to hemophagocytic disorders, are increasingly recognized in a host of infectious and possible even allergic CSS. However, since addressing the primary defect(s) driving CSS is critical to restoring immunologic balance, it is critical to be able to understand and differentiate the mechanisms by which various CSS arrive at their final common pathway.

We propose a framework for understanding CSS wherein a careful assessment for the presence of host and environmental contributors to CSS will guide a rational therapeutic approach (Figure 2). A greater understanding of the mechanisms by which host and environmental factors contribute to CSS, as well as more precise knowledge of how our therapeutics alter those mechanisms, will allow even more precise direction of treatment.

Figure 2
Conceptual model of various cytokine storm syndromes on a spectrum based on the nature of their mechanism of inflammation.


After completion of this article the read should be able to:

  1. Identify clinical similarities and differences between the variety of Cytokine Storm Syndromes.
  2. Describe the clinical and immunologic hallmarks of Macrophage Activation Syndrome and Hemophagocytic Lymphohistiocytosis.
  3. Describe a pathoetiologic framework for understanding Cytokine Storm Syndromes.

Drs. Canna and Behrens have no significant financial disclosures pertaining to this article.


Antigen Presenting Cell
Cytokine Storm Syndrome(s)
Disseminated Intravascular Coagulation
Epstein-Barr Virus
Erythrocyte Sedimentation Rate
Hemophagocytic Lymphohistiocytosis
Malignancy-associated Hemophagocytic Syndrome
Multiple Organ Dysfunction Syndrome
Natural Killer
Systemic Inflammatory Response Syndrome
Systemic Juvenile Idiopathic Arthritis
Systemic Lupus Erythematosus
Toll-like Receptor
X-linked Lymphoproliferative Disorder


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Contributor Information

Scott W. Canna, Division of Rheumatology, The Children’s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, Telephone: 267-426-5278, FAX: 215-590-1258.

Edward M. Behrens, Division of Rheumatology, The Children’s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, Telephone: 267-426-0142, FAX: 215-590-1258.


1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992 Jun;20(6):864–874. [PubMed]
2. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2005 Jan;6(1):2–8. [PubMed]
3. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124–131. [PubMed]
4. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007 May;34(5):1133–1138. [PubMed]
5. Kuwata K, Yamada S, Kinuwaki E, Naito M, Mitsuya H. Peripheral hemophagocytosis: An early indicator of advanced systemic inflammatory response syndrome/hemophagocytic syndrome. Shock. 2006 Apr;25(4):344–350. [PubMed]
6. Imahashi N, Inamoto Y, Ito M, et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011 Apr 18; [PubMed]
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006 Nov;6(11):823–835. [PubMed]
8. Jyonouchi S. [Accessed November 1, 2011];Immunodeficiency Search. 2011
9. Pachlopnik Schmid J, Cote M, Menager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunological reviews. 2010 May;235(1):10–23. [PubMed]
10. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T-cells and interferon gamma are essential for the disorder. Blood. 2004 Aug 1;104(3):735–743. [PubMed]
11. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of Tcell activation. Blood. 2011 May 23; [PubMed]
12. Crozat K, Hoebe K, Ugolini S, et al. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med. 2007 Apr 16;204(4):853–863. [PMC free article] [PubMed]
13. Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B. Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood. 2011 Jun 16;117(24):6582–6588. [PubMed]
14. Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011 Feb 16; [PubMed]
15. Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) Blood. 2011 Feb 3;117(5):1522–1529. [PubMed]
16. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002 Dec;44(3):259–272. [PubMed]
17. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med. 2009 May;10(3):387–392. [PubMed]
18. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006 May;148(5):683–686. [PubMed]
19. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001 Nov;85(5):421–426. [PMC free article] [PubMed]
20. Hoffman HM, Brydges SD. Genetic and molecular basis of inflammasome-mediated disease. J Biol Chem. 2011 Apr 1;286(13):10889–10896. [PMC free article] [PubMed]
21. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003 Mar;142(3):292–296. [PubMed]
22. Villanueva J, Lee S, Giannini EH, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7(1):R30–37. [PMC free article] [PubMed]
23. Vastert SJ, van Wijk R, D’Urbano LE, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 2010 Mar;49(3):441–449. [PubMed]
24. Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008 Sep;58(9):2892–2896. [PMC free article] [PubMed]
25. Fall N, Barnes M, Thornton S, et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007 Nov;56(11):3793–3804. [PubMed]
26. Yanagimachi M, Naruto T, Miyamae T, et al. Association of IRF5 Polymorphisms with Susceptibility to Macrophage Activation Syndrome in Patients with Juvenile Idiopathic Arthritis. The Journal of rheumatology. 2011 Jan 15; [PubMed]
27. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011 Jun 1;121(6):2264–2277. [PMC free article] [PubMed]
28. Guggemoos S, Hangel D, Hamm S, Heit A, Bauer S, Adler H. TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J Immunol. 2008 Jan 1;180(1):438–443. [PubMed]
29. Santiago-Raber ML, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE. J Autoimmun. 2009 Nov-Dec;33(3–4):231–238. [PubMed]
30. Fife MS, Gutierrez A, Ogilvie EM, et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res Ther. 2006;8(5):R148. [PMC free article] [PubMed]
31. Moller JC, Paul D, Ganser G, et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA) Clin Exp Rheumatol. 2010 Nov-Dec;28(6):912–918. [PubMed]
32. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. The Journal of rheumatology. 2010 May;37(5):967–973. [PubMed]
33. Shimizu M, Yokoyama T, Yamada K, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology. 2010 Sep;49(9):1645–1653. [PubMed]
34. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998 Apr;12(2):435–444. [PubMed]
35. Brown DE, McCoy MW, Pilonieta MC, Nix RN, Detweiler CS. Chronic murine typhoid fever is a natural model of secondary hemophagocytic lymphohistiocytosis. PLoS One. 2010;5(2):e9441. [PMC free article] [PubMed]
36. Zoller EE, Lykens JE, Terrell CE, et al. Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med. 2011 Jun 6;208(6):1203–1214. [PMC free article] [PubMed]
37. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. [PubMed]
38. Doyle T, Bhagani S, Cwynarski K. Haemophagocytic syndrome and HIV. Curr Opin Infect Dis. 2009 Feb;22(1):1–6. [PubMed]
39. Veerakul G, Sanpakit K, Tanphaichitr VS, Mahasandana C, Jirarattanasopa N. Secondary hemophagocytic lymphohistiocytosis in children: an analysis of etiology and outcome. J Med Assoc Thai. 2002 Aug;85 (Suppl 2):S530–541. [PubMed]
40. Milner JD, Orekov T, Ward JM, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood. 2010 Oct 7;116(14):2476–2483. [PubMed]
41. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005 May;146(5):598–604. [PubMed]
42. Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol. 2011 Apr;18(4):609–614. [PMC free article] [PubMed]
43. Bleesing J, Prada A, Siegel DM, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007 Mar;56(3):965–971. [PubMed]
44. Wheeler RD, Cale CM, Cetica V, Arico M, Gilmour KC. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2010 Sep;150(6):727–730. [PubMed]
45. Davi S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. The Journal of rheumatology. 2011 Apr;38(4):764–768. [PubMed]
46. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223–235. [PubMed]
47. Marsh RA, Jordan MB, Filipovich AH. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol. 2011 Jun 28; [PMC free article] [PubMed]
48. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002 Oct 1;100(7):2367–2373. [PubMed]
49. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007 Aug;29(8):569–573. [PubMed]
50. Gupta AA, Tyrrell P, Valani R, Benseler S, Abdelhaleem M, Weitzman S. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. Journal of pediatric hematology/oncology. 2009 Feb;31(2):81–84. [PubMed]
51. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003 Jan;3(1):23–35. [PubMed]
52. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005 May 2;201(9):1479–1486. [PMC free article] [PubMed]
53. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011 Feb;63(2):545–555. [PubMed]
54. Behrens EM, Kreiger PA, Cherian S, Cron RQ. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006 Oct;33(10):2081–2084. [PubMed]
55. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011 Jan;17(1):23–27. [PubMed]